Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats

Chinese Medical Journal

Volumn 121, Issue 22, 2008, Pages 2305-2311

  Sun, Li ^a,b   Ke, Yan ^a,c   Zhu, Chun Yun ^a   Tang, Ning ^a   Tian, Deng Ke ^a   Gao, Yue Hong ^a   Zheng, Jian Pu ^a   Bian, Ka ^a,c,d  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Inflammation; Peroxisome proliferator activated receptors; Spontaneously hypertensive rats

Indexed keywords

ACYL COENZYME A OXIDASE; CCAAT ENHANCER BINDING PROTEIN DELTA; CD36 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; HEART; HYPERTENSION; KIDNEY; LIVER; MALE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION;

EID: 62749098629     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200811020-00017     Document Type: Article

References (27)

1. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002; 105: 2296-2302.
2. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
3. Fullert S, Schneider F, Haak E, Rau A, Badenhoop K, Lübben G, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506.
4. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H1037-H1043.
5. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40: 866-871.
6. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, et al. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002; 435: 143-151.
7. Diep, QN, Schifftin EL. Increased expression of peroxisome proliferators activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension 2001; 38: 249-254.
8. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/ enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res 2002; 91: 427-433.
9. Bian K, Gao ZH, Weisbrodt N, Murad F. The nature of heme/iron-induced protein tyrosine nitrution. Proc Natl Acad Sci U S A 2003; 100: 5712-5717.
10. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, et al. Altered constitutive expression of fatty acid metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor-α (PPAR-α). J Biol Chem 1998; 273: 5678-5684.
11. Sun L, Nicholson AC, Hajjar DP, Gotto, AM, Han J. Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res 2003; 44: 1877-1886.
12. Shi XM, Blair HC, Yang X, McDonald JM, Cao X. Tandem repeat of C/EBP binding sites mediates PPAR 2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem, 2000; 76: 518-527.
13. Elberg G, Gimble JM, Tsai SY. Modulation of the murine peroxisome proliferator-activated receptor 2 promoter activity by CCAAT/enhancer binding proteins. J Biol Chem 2000; 275: 27815-27822.
14. Cediel E, Sanz-Rosa D, Oubina MP, de las Heras N, Gonzulez Pacheco FR, Vegazo O, et al. Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regul Integr Comp Physiol 2003; 285: R674-R681.
15. Lincoln TM, Dey NB, Boerth NJ, Cornwell TL, Soff GA. Nitric oxide-cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases. Acta Physiol Scand 1998; 164: 507-515.
16. Salgo MG, Bermudez E, Squadrito GL, Pryor WA. Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes [corrected 1995; 324: 200]. Arch Biochem Biophys 1995; 322: 500-505.
17. Zhuang S, Simon G. Peroxynitrite-induced apoptosis involves activation of multiple caspases in HL-60 cells. Am J Physiol Cell Physiol 2000; 279: C341-C351.
18. Sawa T, Akaike T, Maeda H. Tyrosine nitration by peroxynitrite formed from nitric oxide and superoxide generated by xanthine oxidase. J Biol Chem 2000; 275: 32467-32474.
19. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488.
20. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435-448.
21. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130: 685-696.
22. Bohle A, Muller GA, Wehrmann M, Mackensen-Haen S, Xiao JC. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl 1996; 54: S2-S9.
23. Ma U, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney hit 2001; 59: 1899-1910.
24. Victor NA, Wanderi EW, Gamboa. J, Zhao X, Aronowski J, Deininger K, et al. Alte red PPARγ expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006; 24: 1653-1660.
25. Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, et al. Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma. Mol Pharmacol 2005; 68: 1568-1575.
26. Blanco M, Moro MA, Dávalos A, Leira R, Castellanos M, Serena J, et al. Increased plasma levels of 15-deoxyDelta-prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 2005; 36: 1189-1194.
27. Gilroy DW, Colville-Nash PK Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.